Department of Internal Medicine 3 - Hematology and Internal Oncology

Jutta Hackl
- Department of Internal Medicine 3 - Hematology and Internal Oncology
Person
Christine Haslinger
- Department of Internal Medicine 3 - Hematology and Internal Oncology
Person
Gerhard Hochreiner
- Department of Internal Medicine 3 - Hematology and Internal Oncology
- Faculty of Medicine
Person

4 Finished
22 Active

Therapy-Induced Senescence Tracking with a Real-Time Biosensing Platform
Tekoglu, S. (PI) & Sariciftci, S. N. (PI)
01.10.2025 → 30.09.2027
Project: Funded research › Federal / regional / local authorities
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia (ARGX-113-2402)
Schmitt, C. (PI), Krivic, D. (Researcher), Lichtenauer, N. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Piringer, G. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Solomianyi, O. (Researcher), Schwarz, H. K. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher) & Trathnigg, N. (Researcher)
04.06.2025 → 31.05.2029
Project: Clinical studies › Clinical Study (Industry project)
Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti- CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma (MorningLyte)
Schmitt, C. (PI), Krivic, D. (Researcher), Lichtenauer, N. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Piringer, G. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Solomianyi, O. (Researcher), Schwarz, H. K. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher) & Trathnigg, N. (Researcher)
02.06.2025 → 31.05.2029
Project: Clinical studies › Clinical Study (Industry project)

87 Article
3 Review article
2 Editorial
2 Other contribution
More
- 1 Chapter
- 1 Preprint

Adjuvante Therapie des Kolonkarzinoms im Umbruch
Piringer, G., 01 Sept 2025, Springer Medizin.
Research output: Other contribution
ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer
Piringer, G., 31 Jan 2025, In: memo - Magazine of European Medical Oncology. 18, 1, p. 26-29 4 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
Author Correction: Virus-induced senescence is a driver and therapeutic target in COVID-19
Lee, S., Yu, Y., Trimpert, J., Benthani, F., Mairhofer, M., Richter-Pechanska, P., Wyler, E., Belenki, D., Kaltenbrunner, S., Pammer, M., Kausche, L., Firsching, T. C., Dietert, K., Schotsaert, M., Martínez-Romero, C., Singh, G., Kunz, S., Niemeyer, D., Ghanem, R. & Salzer, H. J. F. & 28 others, Paar, C., Mülleder, M., Uccellini, M., Michaelis, E. G., Khan, A., Lau, A., Schönlein, M., Habringer, A., Tomasits, J., Adler, J. M., Kimeswenger, S., Gruber, A. D., Hoetzenecker, W., Steinkellner, H., Purfürst, B., Motz, R., Di Pierro, F., Lamprecht, B., Osterrieder, N., Landthaler, M., Drosten, C., García-Sastre, A., Langer, R., Ralser, M., Eils, R., Reimann, M., Fan, D. N. Y. & Schmitt, C. A., Feb 2025, In: Nature. 638, 8052, p. E46 1 p.
Research output: Contribution to journal › Article › peer-review

Open Access

140 Invited talk
39 Contributed talk
16 Poster presentation
11 Other talk or presentation
More

Kolorektalkarzinom – later lines
Piringer, G. (Speaker)
02 Dec 2025
Activity: Talk or presentation › Invited talk › science-to-science
Vorsitz: Gastrointestinal Tumore
Piringer, G. (Contributor)
20 Nov 2025
Activity: Talk or presentation › Invited talk › science-to-science
Cellular and Humoral Immune Responses in SARS-CoV-2 Triple-Vaccinated Cancer Patients
Mairhofer, M. (Speaker)
13 Nov 2025
Activity: Talk or presentation › Invited talk › science-to-science

Kepler Science Day - Best Poster
Stegemann, M. (Recipient), 2024
Prize: Prize, award or honor
Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer
Piringer, G. (Recipient), 16 May 2024
Prize: Prize, award or honor

Department of Internal Medicine 3 - Hematology and Internal Oncology

Organisation profile

Fields of science

Jutta Hackl

Christine Haslinger

Gerhard Hochreiner

Therapy-Induced Senescence Tracking with a Real-Time Biosensing Platform

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia (ARGX-113-2402)

Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti- CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma (MorningLyte)

Adjuvante Therapie des Kolonkarzinoms im Umbruch

ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer

Author Correction: Virus-induced senescence is a driver and therapeutic target in COVID-19

Kolorektalkarzinom – later lines

Vorsitz: Gastrointestinal Tumore

Cellular and Humoral Immune Responses in SARS-CoV-2 Triple-Vaccinated Cancer Patients

Kepler Science Day - Best Poster

Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer

Department of Internal Medicine 3 - Hematology and Internal Oncology

Organisation profile

Fields of science

Profiles

Projects

Research output

Activities

Prizes